Terasaka N - Search Results

1

Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.

Honzumi S, Shima A, Hiroshima A, Koieyama T, Terasaka N. Honzumi S, et al. Among authors: terasaka n. Biochim Biophys Acta. 2011 Dec;1811(12):1136-45. doi: 10.1016/j.bbalip.2011.08.009. Epub 2011 Aug 19. Biochim Biophys Acta. 2011. PMID: 21875689

2

HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis.

Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. Tall AR, et al. Among authors: terasaka n. Cell Metab. 2008 May;7(5):365-75. doi: 10.1016/j.cmet.2008.03.001. Cell Metab. 2008. PMID: 18460328 Review.

3

Liver X receptor agonists inhibit tissue factor expression in macrophages.

Terasaka N, Hiroshima A, Ariga A, Honzumi S, Koieyama T, Inaba T, Fujiwara T. Terasaka N, et al. FEBS J. 2005 Mar;272(6):1546-56. doi: 10.1111/j.1742-4658.2005.04599.x. FEBS J. 2005. PMID: 15752369

4

Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor.

Inaba T, Matsuda M, Shimamura M, Takei N, Terasaka N, Ando Y, Yasumo H, Koishi R, Makishima M, Shimomura I. Inaba T, et al. Among authors: terasaka n. J Biol Chem. 2003 Jun 13;278(24):21344-51. doi: 10.1074/jbc.M213202200. Epub 2003 Apr 1. J Biol Chem. 2003. PMID: 12672813

5

T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice.

Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, Inaba T. Terasaka N, et al. FEBS Lett. 2003 Feb 11;536(1-3):6-11. doi: 10.1016/s0014-5793(02)03578-0. FEBS Lett. 2003. PMID: 12586329

6

LXRalpha regulates human CETP expression in vitro and in transgenic mice.

Honzumi S, Shima A, Hiroshima A, Koieyama T, Ubukata N, Terasaka N. Honzumi S, et al. Among authors: terasaka n. Atherosclerosis. 2010 Sep;212(1):139-45. doi: 10.1016/j.atherosclerosis.2010.04.025. Epub 2010 Apr 29. Atherosclerosis. 2010. PMID: 20494359

7

ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.

Terasaka N, Miyazaki A, Kasanuki N, Ito K, Ubukata N, Koieyama T, Kitayama K, Tanimoto T, Maeda N, Inaba T. Terasaka N, et al. Atherosclerosis. 2007 Feb;190(2):239-47. doi: 10.1016/j.atherosclerosis.2006.03.007. Epub 2006 Apr 19. Atherosclerosis. 2007. PMID: 16626720

8

Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe.

Kitayama K, Tanimoto T, Koga T, Terasaka N, Fujioka T, Inaba T. Kitayama K, et al. Among authors: terasaka n. Eur J Pharmacol. 2006 Jul 1;540(1-3):121-30. doi: 10.1016/j.ejphar.2006.04.022. Epub 2006 Apr 29. Eur J Pharmacol. 2006. PMID: 16730694

9

Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists.

Matsui Y, Yamaguchi T, Yamazaki T, Yoshida M, Arai M, Terasaka N, Honzumi S, Wakabayashi K, Hayashi S, Nakai D, Hanzawa H, Tamaki K. Matsui Y, et al. Among authors: terasaka n. Bioorg Med Chem Lett. 2015 Sep 15;25(18):3914-20. doi: 10.1016/j.bmcl.2015.07.047. Epub 2015 Jul 23. Bioorg Med Chem Lett. 2015. PMID: 26238323

10

Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice.

Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR. Yvan-Charvet L, et al. Among authors: terasaka n. J Clin Invest. 2007 Dec;117(12):3900-8. doi: 10.1172/JCI33372. J Clin Invest. 2007. PMID: 17992262 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results